Published in J Clin Pathol on January 01, 2003
Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol (2003) 1.33
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer (2010) 0.90
Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J Clin Pathol (2005) 0.86
Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. J Clin Pathol (2004) 0.85
Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. Virchows Arch (2009) 0.79
Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears. J Low Genit Tract Dis (2005) 0.77
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Detection rates for abnormal cervical smears: what are we screening for? Lancet (1995) 8.92
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet (1997) 6.69
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24
Reconstitution of human telomerase activity in vitro. Curr Biol (1998) 3.51
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer (1993) 3.13
Is cervical screening working? A cytopathologist's view from the United Kingdom. Hum Pathol (1997) 2.97
Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 2.56
Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst (2002) 1.68
Predictive value of human papillomavirus type for histological diagnosis of women with cervical cytological abnormalities. BMJ (1995) 1.16
Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr (1996) 1.15
Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol (2000) 1.11
The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol (2001) 1.08
Cervical cancer screening in France. Eur J Cancer (2000) 0.99
HPV detection and measurement of HPV-16, telomerase, and survivin transcripts in colposcopy clinic patients. J Clin Pathol (2001) 0.97
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol (1998) 0.96
Telomerase activity in gynecological tumors. Clin Cancer Res (1996) 0.94
Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res (1998) 0.91
Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol (2000) 0.88
Telomerase in (pre)neoplastic cervical disease. Hum Pathol (2000) 0.86
Telomerase, cervical cancer, and human papillomavirus. Clin Lab Med (2000) 0.85
Telomerase-A molecular marker for cervical cancer screening. Int J Gynecol Cancer (2001) 0.84
Serial quantitation of HPV-16 in the smears of women with mild and moderate dyskaryosis. J Med Virol (1995) 0.80
Every woman with an abnormal cervical smear should be referred for treatment: debate. Clin Obstet Gynecol (1995) 0.80
HPV testing: where are we now? Anticancer Res (2001) 0.78
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol (1996) 2.94
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res (2006) 2.56
Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. BMJ (1993) 2.50
Neutral amino acid transport by membrane vesicles of Streptococcus cremoris is subject to regulation by internal pH. J Bacteriol (1987) 2.44
Elimination of uninformative variables for multivariate calibration. Anal Chem (1996) 2.30
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet (1999) 2.27
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
Severe exacerbations predict excess lung function decline in asthma. Eur Respir J (2007) 2.18
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy (2006) 1.99
Childhood factors associated with asthma remission after 30 year follow up. Thorax (2004) 1.90
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur Respir J (2007) 1.90
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol (2002) 1.81
Transport of branched-chain amino acids in membrane vesicles of Streptococcus cremoris. J Bacteriol (1987) 1.72
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood (1995) 1.71
Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol (1987) 1.71
Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol (2012) 1.70
Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer (2008) 1.65
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood (1998) 1.63
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy (2004) 1.55
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol (2004) 1.52
Pesticides and other occupational exposures are associated with airway obstruction: the LifeLines cohort study. Occup Environ Med (2013) 1.50
Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol (2012) 1.50
Tumour infiltration depth ≥4 mm is an indication for an elective neck dissection in pT1cN0 oral squamous cell carcinoma. Oral Oncol (2011) 1.48
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther (2006) 1.44
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) (2003) 1.43
Large-amplitude spin dynamics driven by a THz pulse in resonance with an electromagnon. Science (2014) 1.41
[Surgical treatment of early-stage vulva carcinoma and the complications of the operation]. Ned Tijdschr Geneeskd (2005) 1.41
Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol (2002) 1.39
Residual infrarenal aortic neck following endovascular and open aneurysm repair. Eur J Vasc Endovasc Surg (2012) 1.38
Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol (2010) 1.38
Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut (2002) 1.38
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
The clinical trail of TRAIL. Eur J Cancer (2006) 1.35
Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood (1995) 1.34
Acute effects of urban air pollution on respiratory health of children with and without chronic respiratory symptoms. Occup Environ Med (1999) 1.32
Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene (2012) 1.31
Nanoscale spin reversal by non-local angular momentum transfer following ultrafast laser excitation in ferrimagnetic GdFeCo. Nat Mater (2013) 1.31
Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. Biochem Biophys Res Commun (2006) 1.31
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol (2006) 1.24
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood (2000) 1.24
Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene (1996) 1.24
Molecular imaging of breast cancer. Breast (2009) 1.22
Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol (1996) 1.21
Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev (2003) 1.19
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer (1998) 1.19
Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J (2005) 1.18
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Predictive value of human papillomavirus type for histological diagnosis of women with cervical cytological abnormalities. BMJ (1995) 1.16
Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia (2006) 1.16
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol (2009) 1.16
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol (2006) 1.16
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol (2001) 1.14
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer (2004) 1.14
Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol (2001) 1.14
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12